Longboard Pharmaceuticals
Stock Forecast, Prediction & Price Target
Longboard Pharmaceuticals Financial Estimates
Longboard Pharmaceuticals Revenue Estimates
Longboard Pharmaceuticals EBITDA Estimates
Longboard Pharmaceuticals Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $2.58M Low: $2.58M High: $2.58M avg. 0% | Avg: $4.83M Low: $4.83M High: $4.83M avg. 87.38% | Avg: $66.06M Low: $66.06M High: $66.06M avg. 1266.58% | Avg: $261.05M Low: $261.05M High: $261.05M avg. 295.14% |
Net Income
% change YoY
| $-27.73M N/A | $-43.09M -55.38% | $-54.42M -26.29% | Avg: $-91.01M Low: $-62.27M High: $-38.88M avg. -67.23% | Avg: $-115.99M Low: $-76.58M High: $-45.22M avg. -27.44% | Avg: $-62.57M Low: $-62.57M High: $-62.57M avg. 46.05% | Avg: $-12.72M Low: $-12.72M High: $-12.72M avg. 79.66% |
EBITDA
% change YoY
| $-27.83M N/A | $-44.79M -60.92% | $-56.75M -26.68% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.62 N/A | -$2.51 -54.93% | -$2.39 4.78% | Avg: -$2.28 Low: -$2.74 High: -$1.71 avg. 4.41% | Avg: -$2.63 Low: -$3.37 High: -$1.99 avg. -15.33% | Avg: -$2.75 Low: -$2.75 High: -$2.75 avg. -4.50% | Avg: -$0.56 Low: -$0.56 High: -$0.56 avg. 79.66% |
Operating Expenses
% change YoY
| $27.83M N/A | $44.79M 60.91% | $56.75M 26.69% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Longboard Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 7.75% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -62.27M, average is -91.01M and high is -38.88M.
What is Longboard Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 412.27% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $2.58M, average is $2.58M and high is $2.58M.
What is Longboard Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 16.06% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$2.74, average is -$2.28 and high is $-1.71.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Longboard Pharmaceuticals stock. The most successful analyst is Kalpit Patel.